eslicarbazepine acetate

This medicine is authorised for use in the European Union.


Zebinix is an epilepsy medicine used to treat adults with partial-onset seizures (epileptic fits) with or without secondary generalisation. This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness or a sudden sense of fear. Secondary generalisation occurs when the overactivity later reaches the whole brain. Zebinix can be taken on its own, in newly diagnosed epilepsy, or can be added to existing antiepileptic medicines.

Zebinix can also be used in adolescents and children above 6 years of age, in combination with existing therapies, to treat partial-onset seizures with or without secondary generalisation.

Zebinix contains the active substance eslicarbazepine acetate.

This EPAR was last updated on 14/03/2022

Authorisation details

Product details
Agency product number
Active substance
eslicarbazepine acetate
International non-proprietary name (INN) or common name
eslicarbazepine acetate
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
BIAL - Portela & Ca, S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
BIAL - Portela & Ca, S.A.
A Avenida da Siderurgia Nacional
PT-4745-457 S. Mamede do Coronado

Product information

04/03/2022 Zebinix - EMEA/H/C/000988 - PSUSA/00001267/202104

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
1 rating
1 rating
1 rating